[ad_1]
This “2021 Anti-Parkinson Drug Global Market Report: COVID-19 Impact and Recovery in 2030” Report has been added to ResearchAndMarkets.com provide.
2021 Anti-Parkinson Drug Global Market Report: COVID-19 Impact and Recovery in 2030 provides strategists, marketers, and senior management with the key information needed to evaluate the emergence of global anti-Parkinson drugs after the closure of COVID-19.
The major players in the anti-Parkinson drug market are GlaxoSmithKline, Pfizer, Merck, Novartis, Roche, UCB SA, Teva Pharmaceuticals, AbbVie and Mylan.
The global anti-Parkinson drug market is expected to grow from USD 5.3 billion in 2020 to USD 5.55 billion in 2021, with a compound annual growth rate (CAGR) of 4.7%.
The growth was mainly due to the company rescheduling operations and recovering from the effects of COVID-19, which earlier led to restrictive containment measures, including social distancing, remote work, and the closure of business activities, which led to operational challenges .
It is estimated that by 2025, the market will reach USD 7.78 billion at a compound annual growth rate of 9%.
The anti-parkinsonian drug market includes the sale of drugs used to treat Parkinson’s disease (PD), which are produced by institutions that produce these drugs. Parkinson’s disease is a neurodegenerative disease that mainly affects dopaminergic neurons in the substantia nigra in specific areas of the brain and interferes with body movement. People with PD may experience tremors, slow movement, stiffness, gait and balance problems.
The anti-Parkinson drug market covered in this report is divided into levodopa/carbidopa by drug category; dopamine receptor agonists; b-type monoamine oxidase (MAO-b) inhibitors; catechol-o-methyltransferase (COMT)-inhibitors; anticholinergics; other drugs. It is also divided into oral administration according to the route of administration; injection; transdermal and through distribution channels into hospital pharmacies; retail pharmacies; online pharmacies.
The government and enterprises increase investment in the research and development of Parkinson’s disease drugs is a major trend in the anti-Parkinson’s disease drug market. For example, according to a report released by the Parkinson Foundation in 2018, the foundation allocated US$6 million for Parkinson’s disease (PD) research.
In January 2019, the UK Parkinson’s Disease UK Research and Support Charity announced an investment of US$1.9 million (£1.5 million) in its drug discovery program to develop new gene transcription regulators for Parkinson’s disease. Therefore, increasing investment in the development of Parkinson’s drugs is expected to promote the development of the anti-Parkinson drug market.
In June 2019, AbbVie Inc., a global research-driven biopharmaceutical company, announced the acquisition of Dublin-based pharmaceutical company Allergan plc for $63 billion. With Allergan’s diversified product portfolio, AbbVie is expected to strengthen the company’s position in the international biopharmaceutical market.
AbbVie invests in neuroscience, multiple sclerosis, Alzheimer’s disease, and studies the underlying diseases of Parkinson’s disease. Allergan plc is a pharmaceutical company dedicated to developing, manufacturing and commercializing branded pharmaceutical, biological, surgical, equipment and regenerative medicine products for patients worldwide.
It is expected that the increase in the elderly population and the surge in Parkinson’s disease (PD) cases will drive the demand for the anti-Parkinson drug market. PD usually occurs in people over 60 years of age. According to data from the United Nations Department of Economic and Social Affairs, in 2019, 1 in 11 people worldwide is over 65 years old, and this number is expected to increase to one-sixth by the end of 2050.
In addition, according to statistics released by the Michael J. Fox Parkinson Research Foundation in June 2019, more than 1 million Americans suffer from PD. Therefore, the degeneration of neurons in the elderly population and the surge in Parkinson’s disease cases are driving market growth.
The high cost of Parkinson’s disease treatment is expected to limit the growth of the anti-Parkinson’s disease drug market during the forecast period. According to statistics released by the Michael J. Fox Parkinson Research Foundation in June 2019, the economic burden of Parkinson’s disease on patients, families, and the federal government is increasing.
In the United States, the total cost of Parkinson’s disease to individuals, families and governments is US$51.9 billion per year, of which US$25.4 billion is used for direct medical expenses (including hospitalization and medication). Therefore, the high cost of Parkinson’s disease treatment is expected to affect the anti-Parkinson’s disease drug market.
Key topics covered:
1.executive Summary
2. Market characteristics of anti-Parkinson drugs
3. Anti-Parkinson Drug Market Trends and Strategies
4. The impact of COVID-19 against Parkinson’s drugs
5. Anti-Parkinson drug market size and growth
5.1. Global anti-Parkinson drug historical market, 2015-2020, billion U.S. dollars
5.2. Global anti-Parkinson drug market forecast, 2020-2025F, 2030F, billion US dollars
6. Anti-Parkinson Drug Market Segmentation
6.1. Global anti-Parkinson drug market, divided by drug category, history and forecast, 2015-2020, 2020-2025F, 2030F, billion US dollars
-
Levodopa/Carbidopa
-
Dopamine receptor agonists
-
Monoamine oxidase type B (MAO-B) inhibitor
-
Catechol-O-methyltransferase (COMT)-inhibitor
-
Anticholinergics
-
Other drugs
6.2. Global anti-Parkinson drug market, segmented by route of administration, history and forecast, 2015-2020, 2020-2025F, 2030F, billion US dollars
-
oral
-
injection
-
Transdermal
6.3. Global anti-Parkinson drug market, segmented by distribution channels, history and forecast, 2015-2020, 2020-2025F, 2030F, billion US dollars
-
Hospital pharmacy
-
Retailer pharmacy
-
Online pharmacy
7. Regional and Country Analysis of Anti-Parkinson Drugs Market
7.1. Global anti-Parkinson drug market, divided by region, history and forecast, 2015-2020, 2020-2025F, 2030F, billion US dollars
7.2. The global anti-Parkinson drug market, divided by country, history and forecast, 2015-2020, 2020-2025F, 2030F, billion US dollars
Companies mentioned
-
GlaxoSmithKline
-
Pfizer
-
Merck
-
Novartis
-
Roche
-
University of California, San Francisco
-
Teva Pharmaceutical
-
AbbVie
-
Mylan
-
Boehringer Ingelheim
-
Orion Pharmaceuticals
-
Arcadia Pharmaceuticals
-
Sun Pharmaceutical
-
Walkhart
-
Dr. Reddy’s
-
Intas
-
United States WorldMeds
-
Zedus Cadilla
-
Cipla
-
Stride
-
1 A pharmaceutical company
-
Upsher-Smith
-
Lingbei
-
Vertical Pharmaceutical Co., Ltd.
-
Zamboanga Pharmaceutical
-
M Somerset Pharmaceuticals
-
Walkhart
For more information about this report, please visit https://www.researchandmarkets.com/r/32oq92
View the source version on businesswire.com: https://www.businesswire.com/news/home/20210615005642/en/
[ad_2]
Source link
